Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Chief Medical Officer | August 03, 2026 | August 05, 2026 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | Chief Medical Officer | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,611 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 6,551 · Balance 12,611 F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,333,333 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 1,333,333 · Balance 1,333,333 F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock.
F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:08 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,551 | $1.65 | $10,809.15 |
DisclosureSEC source: 0001628280-26-053512 · wk-form4_1785964133.xml · nonDerivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,611 F1 · price: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:47 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001881045-26-000002 · wk-form4_1775249255.xml · derivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| December 11, 2025 Filed Dec 22, 2025 22:41 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001881045-25-000005 · wk-form4_1766443306.xml · derivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2035-12-10 F1 · derivative.exercise_date: This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:25 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 6,060 | $1.65 | $9,999.00 |
DisclosureSEC source: 0001881045-25-000003 · wk-form4_1757622320.xml · nonDerivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,060 F1 · price: On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:08 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001628280-25-016484 · wk-form4_1743710881.xml · derivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:13 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 1,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004042 · form4.xml · derivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333,333 Underlying: Class A Common Stock · 1,333,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:07 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | SaleClass A Common Stock | 12,162 | $1.13 | $13,743.06 |
DisclosureSEC source: 0001062993-23-001324 · form4.xml · nonDerivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,333 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.03 to $1.335, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:05 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionRestricted Stock Units · Derivative | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001040 · form4.xml · derivative · entry 2 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,533 Underlying: Common Stock · 30,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F3 · derivative.exercise_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. F3 · derivative.expiration_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:05 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionCommon Stock | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001040 · form4.xml · nonDerivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,075 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:43 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 93,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004982 · form4.xml · derivative · entry 3 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,333 Underlying: Common Stock · 93,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F3 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. F3 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:43 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 73,528 | $0.00 Strike: $4.06 | $0.00 |
DisclosureSEC source: 0001062993-22-004982 · form4.xml · derivative · entry 2 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,528 Underlying: Common Stock · 73,528 shares Expires 2032-02-16 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on January 14, 2023 and an additional 2.0833 and 1/3% of the shares shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 220,862 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 8 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,862 Underlying: Common Stock · 220,862 shares Expires 2031-01-26 F12 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 150,000 shares of common stock of Private Pear for $1.89 per share. F11 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on January 26, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 103,068 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 7 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,068 Underlying: Common Stock · 103,068 shares Expires 2030-03-24 F10 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.60 per share. F9 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on March 24, 2021 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 88,344 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 6 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,344 Underlying: Common Stock · 88,344 shares Expires 2029-03-14 F8 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 60,000 shares of common stock of Private Pear for $1.58 per share. F7 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on March 14, 2020 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 103,068 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 5 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,068 Underlying: Common Stock · 103,068 shares Expires 2028-03-21 F6 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 70,000 shares of common stock of Private Pear for $1.05 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 176,689 | Not disclosed Strike: $0.14 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 4 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,689 Underlying: Common Stock · 176,689 shares Expires 2026-05-10 F5 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 120,000 shares of common stock of Private Pear for $0.20 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 44,172 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 3 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,172 Underlying: Common Stock · 44,172 shares Expires 2027-12-13 F4 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 30,000 shares of common stock of Private Pear for $1.00 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 73,620 | Not disclosed Strike: $0.02 | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · derivative · entry 2 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,620 Underlying: Common Stock · 73,620 shares Expires 2025-05-05 F3 · price: Received in accordance with the terms of the Business Combination Agreement in exchange for an option to acquire 50,000 shares of common stock of Private Pear for $0.02 per share. F2 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:23 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantClass A Common Stock | 73,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-012387 · form4.xml · nonDerivative · entry 1 Maricich Yuri · CIK 0001881045 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,620 F1 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for 50,000 shares of common stock of Private Pear previously held by Mr. Maricich. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.